Research Triangle Park
82 articles with TransEnterix
Senhance Ultrasonic advanced energy capability broadens potential applicability of Senhance surgery in the United States
TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California.
TransEnterix, Inc. today announced its naming to Deloitte’s 2018 Technology Fast 500TM, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors.
TransEnterix, Inc. (NYSE American:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the Stifel 2018 Healthcare Conference at The Lotte New York Palace Hotel in New York City.
TransEnterix Schedules Third Quarter 2018 Financial and Operating Results Conference Call for November 8, 2018
Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will host a conference call to discuss these results
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
TransEnterix to Showcase First Digital Laparoscopic Surgical Platform, the Senhance Surgical System, at American College of Surgeons Clinical Congress 2018
Experience Senhance Surgery at TransEnterix Booth #577
Receives FDA 510(k) clearance for 3mm instrument set as well as additional 5mm instruments, advancing minimally invasive capabilities within digital laparoscopy
Announces four Senhance system sales in third quarter of 2018
Filed 510(k) submission for Senhance Ultrasonic, broadening the potential applicability of Senhance surgery in the U.S.
Total revenue of $6.4 million, including the sale of four Senhance Systems
TransEnterix Schedules Second Quarter 2018 Financial and Operating Results Conference Call for August 7, 2018
TransEnterix, Inc. announced that it plans to release second quarter 2018 financial and operating results before the market opens on Tuesday, August 7, 2018.
Announces fourth Senhance System sale in second quarter of 2018
Receives FDA 510(k) clearance for laparoscopic inguinal hernia and laparoscopic cholecystectomy procedures
TransEnterix Announces FDA 510(k) Submission for Senhance Indication Expansion to More than Double Addressable Market in the U.S. and Provides Commercial Update
TransEnterix today announced the Company has filed a FDA 510(k) submission to expand the indication for use of its Senhance Surgical System, and provided an update about commercial results thus far for the quarter ending March 31, 2018.
During the quarter ending December 31, 2017, the Company sold two Senhance Systems for total revenue of approximately $3.3 million.
TransEnterix announced that the Company has entered into an agreement with Great Belief International Limited (GBIL), to advance the SurgiBot System towards global commercialization.
TransEnterix announced that Florida Hospital entered into an agreement to purchase the Company’s Senhance Surgical Robotic System.
The Company had cash and restricted cash of approximately $30.9 million as of September 30, 2017, of which $6.4 million was restricted.
TransEnterix to Feature Senhance Surgical System at AAGL: Advancing Minimally Invasive Gynecology Worldwide
The congress will be held November 12-16, 2017 in the Washington, DC area at the Gaylord National Resort and Convention Center at National Harbor.